Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2

Abstract Here we report a recombinant baculoviral vector-based DNA vaccine system against Middle East respiratory syndrome coronavirus (MERS-CoV) and the severe acute respiratory syndrome coronavirus-2 (SARS-CoV2). A non-replicating recombinant baculovirus expressing the human endogenous retrovirus...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hansam Cho, Yuyeon Jang, Ki-Hoon Park, Hanul Choi, Aleksandra Nowakowska, Hee-Jung Lee, Minjee Kim, Min-Hee Kang, Jin-Hoi Kim, Ha Youn Shin, Yu-Kyoung Oh, Young Bong Kim
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c8803c6f22ea41d48cca2dd63dd88fbf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c8803c6f22ea41d48cca2dd63dd88fbf
record_format	dspace
spelling	oai:doaj.org-article:c8803c6f22ea41d48cca2dd63dd88fbf2021-12-02T11:39:20ZHuman endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV210.1038/s41541-021-00303-w2059-0105https://doaj.org/article/c8803c6f22ea41d48cca2dd63dd88fbf2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41541-021-00303-whttps://doaj.org/toc/2059-0105Abstract Here we report a recombinant baculoviral vector-based DNA vaccine system against Middle East respiratory syndrome coronavirus (MERS-CoV) and the severe acute respiratory syndrome coronavirus-2 (SARS-CoV2). A non-replicating recombinant baculovirus expressing the human endogenous retrovirus envelope gene (AcHERV) was constructed as a DNA vaccine vector for gene delivery into human cells. For MERS-CoV vaccine construction, DNA encoding MERS-CoV S-full, S1 subunit, or receptor-binding domain (RBD) was inserted into the genome of AcHERV. For COVID19 vaccine construction, DNA encoding SARS-CoV2 S-full or S1 or a MERS-CoV NTD domain-fused SARS-CoV2 RBD was inserted into the genome of AcHERV. AcHERV-DNA vaccines induce high humoral and cell-mediated immunity in animal models. In challenge tests, twice immunized AcHERV-MERS-S1 and AcHERV-COVID19-S showed complete protection against MERS-CoV and SARS-CoV2, respectively. Unlike AcHERV-MERS vaccines, AcHERV-COVID19-S provided the greatest protection against SARS-CoV2 challenge. These results support the feasibility of AcHERV-MERS or AcHERV-COVID19 vaccines in preventing pandemic spreads of viral infections.Hansam ChoYuyeon JangKi-Hoon ParkHanul ChoiAleksandra NowakowskaHee-Jung LeeMinjee KimMin-Hee KangJin-Hoi KimHa Youn ShinYu-Kyoung OhYoung Bong KimNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Hansam Cho Yuyeon Jang Ki-Hoon Park Hanul Choi Aleksandra Nowakowska Hee-Jung Lee Minjee Kim Min-Hee Kang Jin-Hoi Kim Ha Youn Shin Yu-Kyoung Oh Young Bong Kim Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2
description	Abstract Here we report a recombinant baculoviral vector-based DNA vaccine system against Middle East respiratory syndrome coronavirus (MERS-CoV) and the severe acute respiratory syndrome coronavirus-2 (SARS-CoV2). A non-replicating recombinant baculovirus expressing the human endogenous retrovirus envelope gene (AcHERV) was constructed as a DNA vaccine vector for gene delivery into human cells. For MERS-CoV vaccine construction, DNA encoding MERS-CoV S-full, S1 subunit, or receptor-binding domain (RBD) was inserted into the genome of AcHERV. For COVID19 vaccine construction, DNA encoding SARS-CoV2 S-full or S1 or a MERS-CoV NTD domain-fused SARS-CoV2 RBD was inserted into the genome of AcHERV. AcHERV-DNA vaccines induce high humoral and cell-mediated immunity in animal models. In challenge tests, twice immunized AcHERV-MERS-S1 and AcHERV-COVID19-S showed complete protection against MERS-CoV and SARS-CoV2, respectively. Unlike AcHERV-MERS vaccines, AcHERV-COVID19-S provided the greatest protection against SARS-CoV2 challenge. These results support the feasibility of AcHERV-MERS or AcHERV-COVID19 vaccines in preventing pandemic spreads of viral infections.
format	article
author	Hansam Cho Yuyeon Jang Ki-Hoon Park Hanul Choi Aleksandra Nowakowska Hee-Jung Lee Minjee Kim Min-Hee Kang Jin-Hoi Kim Ha Youn Shin Yu-Kyoung Oh Young Bong Kim
author_facet	Hansam Cho Yuyeon Jang Ki-Hoon Park Hanul Choi Aleksandra Nowakowska Hee-Jung Lee Minjee Kim Min-Hee Kang Jin-Hoi Kim Ha Youn Shin Yu-Kyoung Oh Young Bong Kim
author_sort	Hansam Cho
title	Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2
title_short	Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2
title_full	Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2
title_fullStr	Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2
title_full_unstemmed	Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2
title_sort	human endogenous retrovirus-enveloped baculoviral dna vaccines against mers-cov and sars-cov2
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/c8803c6f22ea41d48cca2dd63dd88fbf
work_keys_str_mv	AT hansamcho humanendogenousretrovirusenvelopedbaculoviraldnavaccinesagainstmerscovandsarscov2 AT yuyeonjang humanendogenousretrovirusenvelopedbaculoviraldnavaccinesagainstmerscovandsarscov2 AT kihoonpark humanendogenousretrovirusenvelopedbaculoviraldnavaccinesagainstmerscovandsarscov2 AT hanulchoi humanendogenousretrovirusenvelopedbaculoviraldnavaccinesagainstmerscovandsarscov2 AT aleksandranowakowska humanendogenousretrovirusenvelopedbaculoviraldnavaccinesagainstmerscovandsarscov2 AT heejunglee humanendogenousretrovirusenvelopedbaculoviraldnavaccinesagainstmerscovandsarscov2 AT minjeekim humanendogenousretrovirusenvelopedbaculoviraldnavaccinesagainstmerscovandsarscov2 AT minheekang humanendogenousretrovirusenvelopedbaculoviraldnavaccinesagainstmerscovandsarscov2 AT jinhoikim humanendogenousretrovirusenvelopedbaculoviraldnavaccinesagainstmerscovandsarscov2 AT hayounshin humanendogenousretrovirusenvelopedbaculoviraldnavaccinesagainstmerscovandsarscov2 AT yukyoungoh humanendogenousretrovirusenvelopedbaculoviraldnavaccinesagainstmerscovandsarscov2 AT youngbongkim humanendogenousretrovirusenvelopedbaculoviraldnavaccinesagainstmerscovandsarscov2
_version_	1718395727321759744

Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2

Ejemplares similares